ERBB2 and osteosarcoma: However, encouraging safety data from nine patients with osteosarcoma who received 28ζ CAR targeting HER2 transduced T cells at doses ranging from 104–106 cells/m2 without conditioning (NCT00902044) were reported at the American Association for Cancer Research (AACR) 2012 by Ahmed et al. at BCM (Ahmed et al., 2014).